Literature DB >> 25679082

Timing of percutaneous coronary intervention in troponin-negative patients with acute coronary syndrome without persistent ST-segment elevation: preliminary results and status quo in German chest pain units.

Frank Breuckmann1, Matthias Hochadel, Thomas Münzel, Evangelos Giannitsis, Thomas Voigtländer, Jochen Senges.   

Abstract

OBJECTIVE: Management of acute coronary syndromes without persistent ST-segment elevation (NSTE-ACS) and unstable angina pectoris (UAP) remains challenging. The study aimed to analyze the current management of UAP patients in German chest pain units focussing on the different time lines of invasive strategy.
METHODS: A total of 1400 UAP patients admitted to a certified chest pain unit were enrolled. Analyses of high-risk criteria with indication for invasive management and of 3-month clinical outcomes were performed by subgrouping UAP patients to immediate and early invasive (<8 hours), early elective invasive (8-24 hours), late elective invasive (24-72 hours) strategy, and without percutaneous coronary intervention (PCI).
RESULTS: Coronary angiography was performed in 60.6% of the UAP patients, whereas PCI was necessary in 37%. Only 1.4% of the UAP patients obtained immediate PCI within the first 120 minutes. In 16.9%, patients received PCI within the first day of hospitalization or even within the first 8 hours after admission in another 7.7%, although the Global Registry of Acute Coronary Events (GRACE) score at admission was below 140. In the remaining 12.4% of the UAP patients, PCI was performed within 24-72 hours after admission. Those patients exhibited a higher prevalence of secondary risk markers than those with conservative treatment regimen.
CONCLUSIONS: To date, almost two-third of UAP patients at intermediate to high risk receive rapid invasive regimen within the first 24 hours after admission. Oncoming studies will have to analyze its overall guideline-adherence and resulting differences in major adverse events.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25679082     DOI: 10.1097/HPC.0000000000000032

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  6 in total

1.  Nationwide but still inhomogeneous distribution of certified chest pain units across Germany : Need to strengthen rural regions.

Authors:  V Varnavas; T Rassaf; F Breuckmann
Journal:  Herz       Date:  2017-01-23       Impact factor: 1.443

Review 2.  German chest pain unit registry: data review after the first decade of certification.

Authors:  Frank Breuckmann; Tienush Rassaf; Matthias Hochadel; Evangelos Giannitsis; Thomas Münzel; Jochen Senges
Journal:  Herz       Date:  2020-03-30       Impact factor: 1.443

3.  Anti-glioma action of aloe emodin: the role of ERK inhibition.

Authors:  S Mijatovic; D Maksimovic-Ivanic; J Radovic; Dj Miljkovic; Lj Harhaji; O Vuckovic; S Stosic-Grujicic; M Mostarica Stojkovic; V Trajkovic
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

4.  On- versus off-hour care for patients with non-ST-segment elevation myocardial infarction in Germany : Exemplary results within the chest pain unit concept.

Authors:  F Breuckmann; F Remberg; D Böse; J Waltenberger; D Fischer; T Rassaf
Journal:  Herz       Date:  2016-05-19       Impact factor: 1.443

5.  Guideline-conforming timing of invasive management in troponin-positive or high-risk ACS without persistent ST-segment elevation in German chest pain units. Urban university maximum care vs. rural regional primary care.

Authors:  F Breuckmann; F Remberg; D Böse; M Lichtenberg; P Kümpers; H Pavenstädt; J Waltenberger; D Fischer
Journal:  Herz       Date:  2015-09-25       Impact factor: 1.443

6.  How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities.

Authors:  Dieter Fischer; Friederike Remberg; Dirk Böse; Michael Lichtenberg; Philipp Kümpers; Pia Lebiedz; Hermann-Joseph Pavenstädt; Johannes Waltenberger; Frank Breuckmann
Journal:  Eur J Med Res       Date:  2016-03-17       Impact factor: 2.175

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.